insights_auto
Nega ABVX tushdi 17,21%?
Batafsil oʻrganishchevron_right
ABVX:EPA
Abivax SA
63,00 €
arrow_downward
-17,21%(-13,10) 1K
20-noy, 17:38:58 (GMT+1) · EUR
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoABVX tikeri uchun statistika yaratilmoqda...
Ochish
74,50 €
Yuqori
74,50 €
Past
59,30 €
Bozor kapitali
5,57 mlrd
Oʻrtacha hajm
112,96 ming
Hajmi
842,42 ming
52 haftalik eng yuqori
139,00 €
52 haftalik eng past
59,30 €
Aksiya boʻyicha daromad
-5,20 €
Muomaladagi aksiyalar
87,55 mln
Xodimlar soni
98
Ochish
74,50 €
Yuqori
74,50 €
Past
59,30 €
Bozor kapitali
5,57 mlrd
Oʻrtacha hajm
112,96 ming
Hajmi
842,42 ming
52 haftalik eng yuqori
139,00 €
52 haftalik eng past
59,30 €
Aksiya boʻyicha daromad
-5,20 €
Muomaladagi aksiyalar
87,55 mln
Xodimlar soni
98
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
Investing.com
·
3 soat oldin
Why is Abivax stock tumbling today?
Investing.com
·
4 soat oldin
Abivax stock tumbles after Scorpion Capital report questions obefazimod safety
Idéal Investisseur
·
9 soat oldin
Abivax shares fall below their €75.50 floor and drop 11% in one week
Profil
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Abivax SA haqida
CEOMarc de Garidel | Hartmut J. Ehrlich
Xodimlar soni98
Asos solingan4-dek, 2013
Bosh ofislar-
SektorHealth Care
Soha-
Veb-saytabivax.com